EP Vantage: Legal loopholes, price hikes set up aging meds for billions in 2020
29 September 2015
In the land of pharma, off-patent drugs usually translate to lost profits. But things don't always shake out that way, as this week's controversy over Turing Pharma and its massive price hike on a 62-year-old drug shows. Thanks to financial maneuvers for some--and good old-fashioned brand strength for others--companies could collect billion-dollar sales for aging drugs by 2020, according to a new report from EvaluatePharma.
28 September 2015
ReVision Optics, Inc. (RVO®), a leader in implantable presbyopia-correcting corneal inlay technology, announces the submission to the U.S. Food and Drug Administration (FDA) of the fourth and final module of the company’s Premarket Approval (PMA) application for the Raindrop® Near Vision Inlay. The Raindrop is a microscopic hydrogel inlay designed to correct presbyopia, thus reducing or even eliminating the need for reading glasses. The fourth module includes clinical data from more than 300 subjects who have been followed for at least 24 months post-procedure.
Americans overpaying hugely for cancer drugs - study
28 September 2015
Americans are paying way over the odds for some modern cancer drugs, with pharmaceutical companies charging up to 600 times what the medicines cost to make, according to an independent academic study.
Australian subsidies for newer drugs go begging as companies avoid paper chase
28 September 2015
Lower costs for newer medicines through subsidies are going begging in Australia as drug companies increasingly look to avoid putting products through regulation paces needed to qualify, a report in news.com.au said, citing a PwC (PricewaterhouseCoopers) survey of 23 drug companies.
Gene, cell therapy strides expose work still ahead
28 September 2015
Concluding with sessions devoted to regenerative medicine, Biopharm America hosted a panel talk on the state of gene and cell therapy, "a new frontier for all of us," said Frank Borriello, head of search and evaluation for Baxalta Inc., the spinout from Baxter International Inc., of Deerfield, Ill.
Microsoft lands cloud genomics infrastructure deal with UC Santa Cruz
28 September 2015
Microsoft ($MSFT) has captured a little corner of the market for cloud genomics infrastructure. The deal sees the IT giant make its Azure cloud computing platform available to UC Santa Cruz Genomics, which plans to use the system to support its work on the Human Genome Variation Map and other initiatives.
Better Rx needed to treat drugmakers’ PR malady
25 September 2015
Biopharma has a bad PR disease. The diagnosis is pretium offensus, otherwise known as “sticker shock.” The infectious condition has two causes: enormous, inexplicable, overnight price hikes and six-figure drug prices that spread from headlines to become a viral meme in congressional hearings and social media.
Huge Russian plasma products plant moving forward
25 September 2015
In May, Russia's Generium said it would build a massive blood plasma plant in the country to make antibodies, blood coagulants and albumin. Now a Swedish design firm said it starting on the engineering for the project.
Low-cost genomic sequencing on the slate for China with Veritas landing?
25 September 2015
Boston-based Veritas Genetics has set up an R&D center in China's Hangzhou Economic & Technological Development Area aimed at genomic screening and testing product development for an Asian population.
Clearside Biomedical, Inc. Announces 50th Patient Enrolled Using Suprachoroidal Drug Administration
24 September 2015
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the retina and choroid, today announced the enrollment of the 50th patient using Clearside’s proprietary ophthalmic drug administration platform for delivering drugs to the suprachoroidal space (SCS).
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024
The Future of Pharmacy: How Advancements in Technology Are Transforming the Field
23 April 2024
Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032
23 April 2024